CTOs on the Move

Sigma-Tau Pharmaceuticals

www.sigmatau.com

 
Sigma-Tau Pharmaceuticals is a Gaithersburg, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.sigmatau.com
  • 9841 Washingtonian Blvd Ste 500
    Gaithersburg, MD USA 20878
  • Phone: 301.948.1041

Executives

Name Title Contact Details

Similar Companies

Repare Therapeutics

Repare Therapeutics is developing new, precision oncology drugs for patients that target specific vulnerabilities of tumor cells. Its approach integrates insights from several fields of cell biology including DNA repair and synthetic lethality. Repare`s platform combines a proprietary, high throughput, CRISPR‐enabled gene editing target discovery method with high‐resolution protein crystallography, computational biology and clinical informatics.

Arrivo BioVentures

We are a biopharmaceutical company focused on accelerating biologics and small molecules through clinical development that have the potential to improve patient lives. We are a team of seasoned pharmaceutical and start-up professionals with an extensive track record of success. Our expertise is in fast, efficient and high quality drug development. Whether developing a reformulated product or a new chemical entity, our management team has expertise to identify regulatory strategies to expedite the path to approval through efficient clinical programs.

Champion Diagnostics

Champion Diagnostics is a Baton Rouge, LA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Parental Therapy Associates

Parental Therapy Associates is a Altamonte Springs, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

CymaBay

CymaBay Therapeutics is a clinical-stage biopharmaceutical company located in the San Francisco Bay Area focused on developing therapies to treat metabolic diseases with high unmet medical need or serious rare and orphan diseases. We are committed to developing breakthrough medicines that improve the lives of patients and their families. CymaBay was seeded with the assets from an earlier metabolic disease company in which more than $120M was invested to produce a robust pipeline.